【摘要】 用人唾腺腺样囊性癌ACC-2细胞在体内外研究了钙拮抗剂维拉帕米对米托蒽醌抗癌作用的增效作用。体外实验表明,无毒剂量的维拉帕米与米托蒽醌合用可显著增强对ACC-2细胞的杀伤作用,合并用药效果大于两者单用之和,表现为协同作用。~3H-TdR掺入抑制实验发现,米托蒽醌佐以维拉帕米可增强对ACC-2细胞DNA合成的抑制,降低肿瘤细胞的增殖速度。裸鼠体内抑癌实验亦证实了体外实验结果。两药合用明显提高对ACC-2种植瘤的抑瘤率。结果提示有可能将维拉帕米作为米托蒽醌抗癌的增效剂应用于唾腺癌的临床化疗。更多还原

【Abstract】 The potentiation of Mitoxantrone (DHAQ) cytotoxicity by Verapamil (VP) wasinvestigated in human adenocystic carcinoma cells (ACC-2) in vitro and in vivo. Invitro studies showed that DHAQ combined with nontoxic doses of VP exhibited asynergetic cytotoxicity in ACC-2 cells. ～3H-TdR incorporation test indicated that VPenhanced the inhibition of DNA synthesis in ACC-2 cells. In vivo studies also showedVP augmented the growth inhibitory effect of DHAQ on ACC-2 xenografts in nudemice. The results suggest that VP may be used clinically as an antitumor enhancer ofDHAQ.更多还原